Hunan Fangsheng Pharm Co Ltd (SHG:603998) — Market Cap & Net Worth
Market Cap & Net Worth: Hunan Fangsheng Pharm Co Ltd (603998)
Hunan Fangsheng Pharm Co Ltd (SHG:603998) has a market capitalization of $604.61 Million (CN¥4.13 Billion) as of August 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #11260 globally and #3136 in its home market, demonstrating a 0.86% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hunan Fangsheng Pharm Co Ltd's stock price CN¥9.41 by its total outstanding shares 439081360 (439.08 Million). See Hunan Fangsheng Pharm Co Ltd capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Hunan Fangsheng Pharm Co Ltd Market Cap History: 2015 to 2026
Hunan Fangsheng Pharm Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $982.26 Million to $604.61 Million (-1.22% CAGR).
Hunan Fangsheng Pharm Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hunan Fangsheng Pharm Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.41x
Hunan Fangsheng Pharm Co Ltd's market cap is 0.41 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.36x
Hunan Fangsheng Pharm Co Ltd's market cap is 2.36 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.03 Billion | $534.26 Million | $69.76 Million | 1.93x | 14.77x |
| 2017 | $654.77 Million | $720.77 Million | $59.68 Million | 0.91x | 10.97x |
| 2018 | $273.60 Million | $1.05 Billion | $72.99 Million | 0.26x | 3.75x |
| 2019 | $488.46 Million | $1.09 Billion | $78.91 Million | 0.45x | 6.19x |
| 2020 | $359.11 Million | $1.28 Billion | $63.79 Million | 0.28x | 5.63x |
| 2021 | $411.54 Million | $1.57 Billion | $70.04 Million | 0.26x | 5.88x |
| 2022 | $504.53 Million | $1.79 Billion | $285.85 Million | 0.28x | 1.77x |
| 2023 | $704.20 Million | $1.63 Billion | $186.82 Million | 0.43x | 3.77x |
| 2024 | $669.50 Million | $1.78 Billion | $255.22 Million | 0.38x | 2.62x |
| 2025 | $722.19 Million | $1.75 Billion | $306.39 Million | 0.41x | 2.36x |
Competitor Companies of 603998 by Market Capitalization
Companies near Hunan Fangsheng Pharm Co Ltd in the global market cap rankings as of August 7, 2026.
Key companies related to Hunan Fangsheng Pharm Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #505 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #556 globally with a market cap of $48.64 Billion USD ( CN¥332.41 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #625 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #505 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.91 |
| #556 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $48.64 Billion | CN¥52.11 |
| #625 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.80 |
Hunan Fangsheng Pharm Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Hunan Fangsheng Pharm Co Ltd's market cap moved from $982.26 Million to $ 604.61 Million, with a yearly change of -1.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥604.61 Million | -16.28% |
| 2025 | CN¥722.19 Million | +7.87% |
| 2024 | CN¥669.50 Million | -4.93% |
| 2023 | CN¥704.20 Million | +39.57% |
| 2022 | CN¥504.53 Million | +22.60% |
| 2021 | CN¥411.54 Million | +14.60% |
| 2020 | CN¥359.11 Million | -26.48% |
| 2019 | CN¥488.46 Million | +78.53% |
| 2018 | CN¥273.60 Million | -58.22% |
| 2017 | CN¥654.77 Million | -36.44% |
| 2016 | CN¥1.03 Billion | +4.88% |
| 2015 | CN¥982.26 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 7th, 2026 the market cap of Hunan Fangsheng Pharm Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $604.61 Million USD |
| MoneyControl | $604.61 Million USD |
| MarketWatch | $604.61 Million USD |
| marketcap.company | $604.61 Million USD |
| Reuters | $604.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hunan Fangsheng Pharm Co Ltd
Hunan Fangsheng Pharmaceutical Co., Ltd. engages in research, develops, produces, and sells traditional Chinese medicine industry and chemical pharmaceutical products in China. The company offers pharmaceutical manufacturing; and provides cardiovascular and cerebrovascular drugs, skeletal muscle system drugs, orthopedic drugs, respiratory drugs, pediatric drugs, gynecological drugs, and anti-infe… Read more